Dentsply Sirona Analyst Ratings
Morgan Stanley Remains a Buy on DENTSPLY SIRONA (XRAY)
Dentsply Sirona Analyst Ratings
Buy Rating on DENTSPLY SIRONA Amidst Financial Growth and Strategic Expansion Opportunities
Dentsply Sirona Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Globus Medical (GMED) and DENTSPLY SIRONA (XRAY)
Stifel Nicolaus Sticks to Its Hold Rating for DENTSPLY SIRONA (XRAY)
Dentsply Sirona Analyst Ratings
Dentsply Sirona Analyst Ratings
UBS Adjusts Price Target on Dentsply Sirona to $37 From $38, Maintains Buy Rating
DENTSPLY SIRONA: A Buy Rating With Positive Long-Term Growth Prospects Despite Short-Term Challenges
Challenging Growth and Market Pressures Lead to Hold Rating for DENTSPLY SIRONA
Dentsply Sirona Analyst Ratings
Dentsply Sirona Analyst Ratings
DENTSPLY SIRONA: Strong Growth and Efficiency Gains Signal Outperform Rating
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
Barrington Research Reiterates Outperform on Dentsply Sirona, Maintains $41 Price Target
Dentsply Sirona Analyst Ratings
Analysts Conflicted on These Healthcare Names: DENTSPLY SIRONA (XRAY), Xenon (XENE) and Oric Pharmaceuticals (ORIC)